Skip to content

PolitiKit

Lobbying by RAREi - The Canadian Forum for Rare Disease Innovators: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

RAREi - The Canadian Forum for Rare Disease Innovators

Meetings this Parliament
1
With MPs
1
Since Nov 2021
2
Active registrations
1

Most recent reported meeting: Apr 14, 2026.

Registrations in effect

Consultant In effect since Oct 16, 2026

Consultant Johanne Chambers of 3Sixty Public Affairs Inc.

Consultant lobbyists

  • Johanne Chambers Former public office holder

    Formerly Negotiator, Negotiations East Branch, Indian and Northern Affairs Canada (2007–2014)

    Formerly Lawyer, Department of Legal Services for INAC, Department of Justice (2006–2007)

    Formerly Senior Policy Analyst, Treaties, Research, International and Gender Equality Branch, Indian and Northern Affairs Canada (2004–2006)

Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (9)
  • Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.
  • Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.
  • Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
  • Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
  • Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.
  • Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
  • Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.
  • Implementation of the Pharmacare Act and its implications for rare disease medicines.
  • Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.

Registration 942584-367524-12. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by Johanne Chambers · Consultant

    Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines. Read more

    Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

    Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.

    Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.

    Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.

    Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.

    Official report

  • Reported by Johanne Chambers · Consultant

    • Francis Droulin · Member of Parliament, House of Commons

    Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.